Intravenous drips in dermatology: Elixir, evidence, or ethical dilemma?

INTRODUCTION

The growing intersection between dermatology and esthetic medicine has led to the inclusion of therapies traditionally outside the core curriculum of dermatology. Among these, intravenous (IV) drips have gained substantial popularity in recent years. Branded as skin-brightening, anti-aging, detoxifying, or glow-enhancing, these drips are marketed in both medical and non-medical settings, often with bold claims.^[1]

Historically, IV therapies in dermatology have served as essential tools in managing severe conditions such as Stevens–Johnson syndrome, erythroderma, or immunobullous disorders. However, the modern adaptation of IV infusions into esthetic dermatology raises important questions about their scientific validity, safety, and ethical use.

CLINICAL USE IN DERMATOLOGY

IV therapies have well-established indications in dermatological practice, including:

1. IV corticosteroids for acute flares of autoimmune blistering diseases such as pemphigus vulgaris and bullous pemphigoid.^[2]

2. IV antibiotics in severe cutaneous infections, including necrotizing fasciitis and erysipelas.

3. IV immunoglobulin for refractory autoimmune bullous disorders, connective tissue disorders, and toxic epidermal necrolysis.^[3]

4. IV antihistamines for severe or refractory cases of urticaria and anaphylactic reactions.

ESTHETIC AND WELLNESS USE

Beyond their clinical indications, IV therapies are increasingly being used in esthetic medicine and wellness settings for purposes such as [Table 1]:

IV VERSUS ORAL FORMULATIONS

Many ingredients used in esthetic IV drips–such as glutathione, Vitamin C, biotin, and B-complex vitamins–are also available in oral forms. The preference for IV over oral administration is often based on perceived superiority in efficacy, but this distinction deserves critical scrutiny.^[5]

1. Bioavailability and pharmacokinetics IV administration bypasses the gastrointestinal tract, delivering nutrients directly into the bloodstream with 100% bioavailability. This can be beneficial in acute medical situations or patients with malabsorption syndromes.

   Oral formulations, while subject to first-pass metabolism and variable absorption, are generally adequate to meet physiological needs in otherwise healthy individuals. The increased absorption through the IV route does not necessarily translate to improved cosmetic outcomes.

2. Safety and risk profile IV therapy carries procedural risks, including:

   • Local complications (e.g., phlebitis, extravasation)

   • Systemic reactions (e.g., hypersensitivity, anaphylaxis)

   • Infection due to breaches in sterility.

   In contrast, oral formulations are significantly safer, with fewer adverse events and minimal systemic risk when taken at recommended doses.

3. Convenience and compliance

   Oral supplements are non-invasive, convenient, and self-administered, allowing for better patient adherence and less resource utilization. IV drips require clinical settings, trained personnel, and time for administration, making them less practical for long-term use.

4. Cost and accessibility

   Oral formulations are considerably more affordable and widely accessible, making them preferable for most patients. IV drips are cost-intensive and may require multiple sessions, further raising the financial burden on patients, particularly when outcomes are not guaranteed.

5. Clinical justification

   In medical dermatology, IV formulations are justified in situations requiring rapid correction, systemic delivery, or when oral routes are contraindicated. However, in esthetic dermatology, there is little evidence to support that IV administration of vitamins or antioxidants offers superior results over oral intake for cosmetic goals.^[5]

COST-EFFECTIVENESS AND PRACTICAL CONSIDERATIONS

The widespread adoption of IV drips in esthetic dermatology has economic implications that warrant scrutiny, particularly in the absence of robust evidence of efficacy.

1. High cost with unclear benefit

   Esthetic IV drips are often priced between ₹3,000 and ₹15,000 per session in India, with some regimens recommending weekly or biweekly infusions. Cumulative costs over time can become substantial, with no guarantee of clinically significant or sustained benefit, especially in comparison to far cheaper oral alternatives.

2. Commercial incentivization and ethical concerns

   Clinics may promote IV drips aggressively due to higher profit margins compared to oral supplements.This commercialization, coupled with unsubstantiated claims, may create false urgency or unrealistic expectations, undermining informed consent and patient autonomy.

CONCERNS AND ETHICAL CHALLENGES

1. Lack of evidence

   There is a significant gap between the popularity of IV esthetic drips and the quality of clinical evidence supporting them.^[5]

2. Safety profile

   Although marketed as safe, IV therapies are not without risk. Glutathione has been linked to Stevens–Johnson syndrome, hepatic injury, and renal dysfunction in some cases.^[6] The Philippine FDA has issued warnings against IV glutathione for skin lightening, citing risks such as toxic epidermal necrolysis and renal failure.^[7]

3. Unregulated use

   The administration of IV drips in beauty salons or non-medical setups continues largely unchecked. These environments lack clinical oversight, aseptic technique, or appropriate patient screening.

4. Ethical implications

   The dermatological community must balance patient autonomy with medical responsibility. Administering expensive, unproven treatments in the name of esthetics can border on unethical if the risks and benefits are not transparently discussed.^[8]

FUTURE DIRECTIONS

To strike a balance between patient interest and responsible practice, the following steps are essential:

1. Research initiatives: There is a pressing need for well-designed clinical trials to rigorously assess the efficacy and safety of IV drips used in dermatological practice, particularly for cosmetic purposes.

2. Guideline development: Leading dermatological associations, such as the Indian Association of Dermatologists, Venereologists, and Leprologists, should consider developing evidence-based guidelines or position statements to address the clinical use of IV drips.

3. Patient education: It is essential to educate patients that many cosmetic interventions, including IV drips for skin enhancement, may lack robust scientific evidence. Informed decision-making should be encouraged through transparent communication.

CONCLUSION

The rise of IV drips in dermatology represents both an opportunity and a cautionary tale. While there may be potential in exploring IV nutrient therapies for select dermatological indications, the esthetic overuse of these drips, often driven by commerce rather than science, poses significant ethical and clinical challenges. As dermatologists, it is our responsibility to navigate this evolving space with integrity, scientific curiosity, and patient safety in mind.